Bavarian Nordic A/S (OTCMKTS:BVNRY) Posts Quarterly Earnings Results, Beats Expectations By $0.07 EPS

Bavarian Nordic A/S (OTCMKTS:BVNRY - Get Free Report) posted its earnings results on Wednesday. The company reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.40 by $0.07, Zacks reports. Bavarian Nordic A/S had a return on equity of 10.65% and a net margin of 18.33%. The firm had revenue of $299.48 million for the quarter, compared to analyst estimates of $264.06 million.

Bavarian Nordic A/S Stock Performance

BVNRY stock traded up $0.13 during mid-day trading on Friday, reaching $8.08. The company had a trading volume of 5,241 shares, compared to its average volume of 10,917. The company has a market capitalization of $1.91 billion, a price-to-earnings ratio of 11.70 and a beta of 1.83. The firm has a fifty day simple moving average of $8.51 and a 200 day simple moving average of $9.86. Bavarian Nordic A/S has a fifty-two week low of $6.86 and a fifty-two week high of $14.60.

Bavarian Nordic A/S Company Profile

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.